Mandaviya discusses Corbevax production with Biological E Ltd MD

The Minister was briefed on the progress of Biological's upcoming Covid vaccine Corbevax.

Mansukh L. Mandaviya
Mansukh L. Mandaviya
IANS New Delhi
2 min read Last Updated : Aug 06 2021 | 2:12 PM IST

Don't want to miss the best from Business Standard?

The Union Health Minister Mansukh Mandaviya on Friday held a discussion with Biological E Ltd. Managing Director Mahima Datla here.

The Minister was briefed on the progress of Biological's upcoming Covid vaccine Corbevax. He assured the government's support in the production of the Corbevax vaccine to combat the covid pandemic.

"Met Ms Mahima Datla, MD of @Biological_E, who briefed me on the progress of their upcoming #COVID19 vaccine, Corbevax. I assured all the Government support for the vaccine," said Mansukh Mandaviya in a tweet on Friday.

The Hyderabad based drug major Biological E will produce the Johnson & Johnson Covid-19 vaccine. The company plans to produce 75 million to 80 million doses of its own vaccine in a month to boost the country's overall supplies. The vaccine has been developed with Baylor College of Medicine in Houston and Dynavax Technologies Corp.

Meanwhile, India's cumulative Covid-19 vaccination coverage crossed the landmark of 49 crore doses on Thursday.

Cumulatively, 49,53,27,595 vaccine doses have been administered through 57,64,712 sessions, as per the provisional report of the Union Health Ministry. A total of 57,97,808 vaccine doses were administered in the last 24 hours.

However, India continues to report over 40,000 fresh Covid-19 cases on a daily basis. India today reported more than 40,000 cases for the third day running. On Friday, a total of 44,643 fresh cases were reported in the last 24 hours. And a total of 463 persons succumbed to the corona infection in the same span of time in India, said the health bulletin released by the Health and Family Welfare Ministry.

However, India's recovery rate currently stands at 97.36 per cent. India's active Covid infection tally climbed to 4,14,159 on Friday. The active cases constitute 1.30 per cent of the total caseloads in India.

--IANS

avr/dpb

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMansukh Lal MandaviyaBiological E

First Published: Aug 06 2021 | 2:12 PM IST

Next Story